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n 2005 Elias A. Zerhouni, then director of the National Institutes of Health pub-
lished a seminal essay, “Translational and Clinical Science – Time for a New Vi-
sion” in the New England Journal of Medicine.1 This work challenged stakeholders 
in the scientific enterprise to consider new models to “translate the remarkable scien-
tific innovations we are witnessing into health gains for the nation.” Since then debate 
has continued regarding how best to realize the potential of true translational work. 
While gains have certainly been made, historic, structural and philosophic hurdles per-
sist which prevent us from fully achieving this promise.
Clinical Faculty Perspective 
With this background, I offer one 
perspective, that of a clinical faculty 
member at a large public institution who 
has also recently served as a leader of the 
elected faculty body at the University of 
Iowa, on areas we might target as we try 
to take bench-top discoveries to the bed-
side or the clinic. A significant portion of 
my professional time is spent on direct 
patient care. This indeed is what drives 
my goal of participating in the conversa-
tion of how we can provide ever-better 
care for patients with breast cancer and 
ultimately for all patients.  
My personal research spans several 
areas. At my institution I lead federally 
funded clinical trials in my discipline of 
breast oncology. I also direct industry 
funded clinical trials and partner with la-
boratory investigators to bring investiga-
tor-initiated studies to the clinic. One 
study which is currently open for enroll-
ment looks at the role of inhibiting the 
RET receptor in hormone receptor posi-
tive breast cancer. Other translational 
work includes work investigating novel 
agents to treat chemotherapy-induced 
neuropathy and studies looking at new 
circulating serum markers of breast can-
cer.  
Research I direct involves a collabo-
ration of faculty from the Colleges of 
Medicine, Pharmacology and Public 
Health with the objective of utilizing the 
SEER (Surveillance, Epidemiology, and 
End Results program of the National 
Cancer Institute) data and other data 
sources to address questions related to 
breast cancer treatment and outcomes. 
My personal work seeks to answer ques-
tions which directly pertain to our pa-
tients, and looks at issues that we find 
frustrating in the clinic. Finally, I initiated 
and serve as the principal investigator for 
the University of Iowa Breast Molecular 
Epidemiologic Resource, which is a pro-
spective study of tissue and epidemio-
logic data for individuals who are at high 
risk for or are diagnosed with a prolifera-
tive disorder of breast tissue. As of March 
2015 over 1,000 patients have enrolled in 
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this registry. This has served as a re-
source for bench investigators looking at 
a variety of questions in breast cancer. 
Notable recent externally funded work 
includes examining obesity, inflamma-
tion and breast cancer and a study look-
ing at the role of novel fusion transcripts 
in breast cancer.  
There are many areas that we might, 
as a community, elect to focus on to truly 
harness the potential of translational re-
search. With the lens that I bring to clini-
cal research and the healthcare enter-
prise, I put forth three areas that we could 
invest in to more completely produce 
healthcare gains for society: reward all 
members on the bridge from the labora-
tory to the clinic, support and sustain 
women in science, engage society. We 
might further consider that we, at public 
universities in the Midwest, in certain 
ways are uniquely situated to act on these 
opportunities based on our rich tradi-
tions of community and collaboration.  
Reward All Members on the Trans-
lational Bridge from the Laboratory to 
the Clinic: Since the 2005 statement by 
the National Institutes of Health Director, 
scientific leaders have worked to em-
brace this model. An entire body of liter-
ature has evolved on “team science” 
which focuses on collaboration from 
bench to bedside or clinic as well as in 
cross-disciplinary work and cross-insti-
tutional work. Some have shown that 
while such coordination can have a lead-
time, it ultimately demonstrates higher 
productivity with regard to publications 
and inclusion of many co-authors.2 How-
ever meaningful opportunities for re-
spect of all contributions still exist. Tradi-
tional hierarchies in education persist. 
Some argue that clinical research or in-
cluding clinicians in research dilutes the 
rigor of academic work.  
However, fully including clinicians 
in investigations is critical on several in-
creasingly important fronts. Fundamen-
tal research which is linked to applied re-
search is more readily supported by the 
public. Importantly, engaging those de-
livering the products of bench top inves-
tigations to patients further provides the 
opportunity for clinicians to bring back to 
their laboratory colleagues the pertinent, 
unanswered questions. This two-way di-
alogue is vital to making contemporary 
medical research relevant. Opportunities 
to fortify this communication and value 
all members of the translational bridge 
include encouraging diverse research 
portfolios, reconsidering what is valued 
in promotion and tenure and revisiting 
how awards and leadership roles are dis-
tributed.  
Support and Sustain Women in Sci-
ence: Some might argue that women 
have made great advances in participat-
ing in the scientific enterprise. However, 
the barriers to fully including women re-
main. We really need to look no further 
than the very recent comments by Nobel 
Laureate Tim Hunt who stated, “...let me 
tell you about my trouble with 
girls...three things happen when they are 
in the lab. You fall in love with them, they 
fall in love with you, and when you criti-
cize them, they cry.”3 In 2013 Nature ded-
icated an entire issue to the topic of 
women in science. This publication was 
dedicated to a long-time editor Maxine 
Clarke who for years was known for her 
high scientific standards and for asking, 
“Where are the women?”  
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Supporting and sustaining women 
in science is critical, as ultimately unless 
women are equal partners, society will be 
deprived of this intellectual resource. A 
myriad of opportunities exist to fully in-
clude women in our work. Important ad-
vances would include rewarding women 
equally. Equal pay and comparable 
recognition with awards still needs to be 
attained. We also need to make science 
and the environments in which it is prac-
ticed comfortable for women. Do we 
need to feminize science? No. Perhaps 
more aptly we could allow practicing sci-
ence to be feminine. I would argue that in 
breast oncology, I have found a discipline 
which can have a very feminine aspect to 
it – can we expand that to allow it as part 
of other fields, would that help lung can-
cer and colon cancer patients? What 
about research in technology fields? Fi-
nally, we could better understand career 
breaks for having a family (which also ul-
timately helps men on a variety of levels) 
and proportionally give credit as one 
young scientist recently describes.4 In this 
we are asking science to support families, 
which further ensures our sustainability 
and helps all stakeholders.  
Engage Society: The eloquent Har-
vard scientist Stephen Jay Gould who 
could magnetically draw the public to 
science explained his skill once stating, 
“So many scientists think that once they 
figure it out, that's all they have to do, 
and writing it up is just a chore. I never 
saw it that way. Part of the art of any kind 
of total scholarship is to say it well.”5 Per-
haps at no time has this ability to tell our 
story been more relevant than today, 
when funding is short and we need to en-
gage society to garner support for the vi-
tal work of discovery. I am able to deliver 
novel life-saving therapies to women to-
day that were not available just a few 
years ago. Perhaps our community 
should more regularly showcase these in-
credible successes in ways that speak to 
non-scientists? What about the other side 
of this story, when we use the societal re-
sources we are given poorly. Some in ac-
ademia have criticized the Golden Fleece 
award, arguing that to succeed we need 
to have failures. Perhaps this is true to 
some extent, however the days of fund-
ing, philanthropic or governmental, for 
clearly irrelevant research are over. To 
maintain credibility with society we must 
be excellent stewards of public and pri-
vate resources. We must show society, in 
language they understand, that what 
they award us helps overcome disease, 
hunger, poverty and leads to a better 
quality of life. 
In engaging society with our work, 
we have another opportunity to collabo-
rate across the translational bridge. Scien-
tists need to articulate the value of their 
work – but can also collaborate here with 
their clinical colleagues– who sit at the 
nexus with the public and directly under-
stand the value of scientific advances. We 
should use resources wisely and with re-
spect and take opportunities to showcase 
meaningful, transformative research in-
novations. This means when the media 
calls, embrace the chance to discuss our 
projects. While this is not innately com-
fortable for many of us, perhaps we 
should strive to make it more a part of 
our culture, especially at public universi-
ties. 
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Conclusion 
The prospect of better realizing re-
search innovations at the forefront of sci-
ence holds immense promise for im-
proved health and social outcomes. As 
Dr. Zerhouni wrote, “We now aim to 
stimulate the development of a brighter 
vision for translational and clinical re-
search, to ensure that these disciplines re-
main powerful engines of creativity.” I 
have tried to outline several achievable, 
and also imperative opportunities to 
come closer to fully attaining this goal. 
Undoubtedly some barriers will need to 
be removed, as again Dr. Zerhouni out-
lined: “...the NIH has the responsibility to 
work toward dissolving the artificial bar-
riers that inevitably spring up...We perse-
vere in our determination to provide op-
portunities for the research community 
and to challenge the status quo in trans-
formative ways.” Certainly, the shared 
goals of better health outcomes and im-
proved global quality of life held by all 
stakeholders in the research enterprise 
can help move us collectively toward this 
vision.  
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